| Biktarvy | Bictegravir, Embitcitabine, Tenofovir Alafenamide | Gilead Sciences | $5,269 | Chemical | Infectious Diseases | To treat infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen | 7-Feb-18 |
| Symdeko | Tezacaftor; Ivacaftor | Vertex Pharmaceuticals | $2,750 | Chemical | Respiratory Diseases | To treat cystic fibrosis in patients age 12 years and older | 13-Feb-18 |
| Ultomiris | Ravulizumab-cwvz | Alexion Pharmaceuticals | $2,199 | Biological | Rare Diseases / Blood Diseases | To treat paroxysmal nocturnal hemoglobinuria (PNH) | 21-Dec-18 |
| Orilissa | Elagolix Sodium | AbbVie / Neurocrine Biosciences | $2,000 | Chemical | Gynecology | For the management of moderate to severe pain associated with endometriosis | 23-Jul-18 |
| Erleada | Apalutamide | Janssen R&D | $2,000 | Chemical | Oncology / Urology | To treat a certain type of prostate cancer using novel clinical trial endpoint | 14-Feb-18 |
| Lutathera | Lutetium Lu 177 Dotatate | Advanced Accelerator Applications / Novartis Pharmaceuticals Corporation | $2,000 | Chemical | Oncology / Gastroenterology | To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). | 26-Jan-18 |
| Takhzyro | Lanadelumab-flyo | Shire plc | $1,800 | Biological | Genetic Diseases / Immunology | To treat types I and II hereditary angioedema | 23-Aug-18 |
| Olumiant | Baricitinib | Incyte, Eli Lilly | $1,800 | Chemical | Rheumatology | To treat moderately to severely active rheumatoid arthritis | 31-May-18 |
| Xofluza | Baloxavir Marboxil | Shionogi & Co. Ltd, Roche AG | $1,500 | Chemical | Family Medicine / Oncology | For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours. | 24-Oct-18 |
| Libtayo | Cemiplimab-rwlc | Regeneron Pharmaceuticals | $1,400 | Biological | Dermatology / Oncology | To treat cutaneous squamous cell carcinoma (CSCC) | 28-Sep-18 |
| AndexXa | Coagulation Factor Xa (Recombinant), Inactivated | Portola Pharamceuticals | $1,400 | Biological | Haematology | Indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-theratening or uncontrolled bleeding. | 3-May-18 |
| Epidiolex | Cannabidiol | GW Pharmaceuticals, plc | $1,300 | Chemical | Neurology / Pediatrics | To treat rare, severe forms of epilepsy | 25-Jun-18 |
| Onpattro | Patisiran | Alnylam Pharmaceuticals | $1,212 | Chemical | Genetic Diseases / Neurology | To treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients | 10-Aug-18 |
| Crysvita | Burosumab-twza | Ultragenyx Pharmaceutical / Kyowa Hakko Kirin | $1,091 | Biological | Genetic Disease / Musculoskeletal | To treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets | 17-Apr-18 |
| Mektovi | Binimetinib | Array BioPharma Inc. | $1,000 | Chemical | Oncology / Hematology | To treat unresectable or metastatic melanoma | 27-Jun-18 |
| Lokelma | Sodium Zirconium Cyclosilicate | AstraZeneca plc | $1,000 | Chemical | Hematology | To treat hyperkalemia | 18-May-18 |
| Aimovig | Erenumab-aooe | Amgen / Novartis Pharmaceutical Corporation | $1,000 | Biological | Family Medicine / Neurology | For the preventive treatment for migraine | 17-May-18 |
| Vitrakvi | Larotrectinib | Loxo Oncology | $860 | Chemical | Oncology | To treat patients whose cancers have a specific genetic feature (biomarker) | 26-Nov-18 |
| Copiktra | Duvelisib | Verastem Oncology | $850 | Biological | Oncology | To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma | 24-Sep-18 |
| Emgality | Galcanezumab-gnlm | Eli Lilly | $701 | Biological | Neurology | For the preventive treatment of migraine in adults | 27-Sep-18 |
| Galafold | Migalastat | Amicus Therapeutics | $612 | Chemical | Genetic Diseases | To treat treat adults with Fabry disease. | 10-Aug-18 |
| Talzenna | Talazoparib | Pfizer Inc. | $609 | Chemical | Obstetrics / Gynecology | For the treatment of locally advanced or metastatic breast cancer patients with a germline BRCA mutation. | 16-Oct-18 |
| Doptelet | Avatrombopag | Dova Pharmaceuticals | $600 | Chemical | Hematology | To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure | 21-May-18 |
| Nuzyra | Omadacycline | Paratek Pharmaceuticals | $500 | Chemical | Dermatology / Respiratory Diseases / Infectious Diseases | To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections | 3-Oct-18 |
| Ajovy | Fremanezumab-vfrm | Teva Pharmaceutical Industries Ltd. | $500 | Biological | Family Medicine / Neurology | For the preventive treatment of migraine in adults | 14-Sep-18 |
| Lumoxiti | Moxetumomab Pasudotox-tdfk | AstraZeneca plc | $500 | Biological | Oncology / Hematology | To treat hairy cell leukemia | 13-Sep-18 |
| Pifeltro | Doravirine | Merck & Co. | $500 | Chemical | Infectious Diseases | To treat HIV-1 infection in adult patients | 30-Aug-18 |
| Braftovi | Encorafenib | Array BioPharma Inc. | $500 | Chemical | Oncology / Hematology | To treat unresectable or metastatic melanoma | 27-Jun-18 |
| Zemdri | Plazomicin | Achaogen, Inc. | $500 | Chemical | Infectious Diseases | To treat adults with complicated urinary tract infections | 25-Jun-18 |
| Palynziq | Pegvaliase-pqpz | BioMarin | $500 | Biological | Hematology / Oncology | To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU) | 24-May-18 |
| Ilumya | Tildrakizumab-asmn | Merck & Co. / Sun Pharmaceutical Industries | $500 | Biological | Immunology / Dermatology | To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy | 20-Mar-18 |
| Tegsedi | Inotersen | Ionis Pharmaceuticals / Akcea Therapeutics | $497 | Chemical | Internal Medicine / Genetic Disease | To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | 5-Oct-18 |
| Trogarzo | Ibalizumab-uiyk | Theratechnologies / TaiMed Biologics | $401 | Biological | Infectious Diseases | To treat HIV patients who have limited treatment options | 6-Mar-18 |
| Firdapse | Amifampridine | Catalyst Pharmaceuticals/ BioMarin | $375 | Chemical | Musculoskeletal / Neurology | To treat Lambert-Eaton myasthenic syndrome (LEMS) in adults | 28-Nov-18 |
| Tavalisse | Fostamatinib | Rigel Pharmaceuticals | $360 | Chemical | Hematology | To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP) | 17-Apr-18 |
| Xerava | Eravacycline | Tetraphase Pharmaceuticals | $340 | Chemical | Infectious Diseases | To treat complicated intra-abdominal infections in patients 18 years of age and older | 27-Aug-18 |
| Vizimpro | Dacomitinib | Pfizer Inc. | $336 | Biological | Respiratory Diseases / Oncology | To treat metastatic non-small-cell lung cancer | 27-Sep-18 |
| Gamifant | Emapalumab-lzsg | Swedish Orphan Biovitrum AB / Novimmune | $330 | Biological | Immunology | To treat primary hemophagocytic lymphohistiocytosis (HLH) | 20-Nov-18 |
| Annovera | Segesterone Acetate And Ethinyl Estradiol Vaginal System | TherapeuticsMD | $300 | Chemical | Gynecology | New vaginal ring used to prevent pregnancy for an entire year | 10-Aug-18 |
| Tibsovo | Ivosidenib | Agios Pharmaceuticals | $300 | Chemical | Oncology / Hematology | To treat patients with relapsed or refractory acute myeloid leukemia | 20-Jul-18 |
| Daurismo | Glasdegib | Pfizer Inc. | $293 | Chemical | Oncology / Hematology | To treat newly-diagnosed acute myeloid leukemia (AML) in adult patients | 21-Nov-18 |
| Jivi | Antihemophilic Factor (Recombinant), Pegylated | Bayer HealthCare LLC | $273 | Biological | Hematology | Indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for: on demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes | 29-Aug-18 |
| Lorbrena | Lorlatinib | Pfizer Inc. | $263 | Chemical | Pulmonary / Respiratory Diseases | To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer | 2-Nov-18 |
| Xospata | Gilteritinib | Astellas Pharma | $260 | Chemical | Oncology / Hematology | To treat patients who have relapsed or refractory acute myeloid leukemia (AML) | 28-Nov-18 |
| Aemcolo | Rifamycin | Cosmo Pharmaceuticals NV | $250 | Chemical | Infectious Diseases | To treat travelers’ diarrhea | 16-Nov-18 |
| Yupelri | Revefenacin | Theravance Biopharma | $250 | Chemical | Pulmonary / Respiratory Diseases | To treat patients with chronic obstructive pulmonary disease (COPD) | 8-Nov-18 |
| Asparlas | Calaspargase Pegol-mknl | Shire plc | $200 | Biological | Oncology / Hematology | To treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years | 20-Dec-18 |
| Seysara | Sarecycline | Paratek Pharmaceuticals, Actavis | $200 | Chemical | Dermatology | To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older | 1-Oct-18 |
| Elzonris | Tagraxofusp-erzs | Stemline Therapeutics | $130 | Biological | Oncology / Hematology | To treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) | 21-Dec-18 |
| Poteligeo | Mogamulizumab-kpkc | Kyowa Hakko Kirin | $72 | Biological | Oncology / Hematology | To treat two rare types of non-Hodgkin lymphoma | 8-Aug-18 |
| Mulpleta | Lusutrombopag | Shionogi & Co. Ltd | $38 | Chemical | Hepatology / Hematology | To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure | 31-Jul-18 |
| Motegrity | Prucalopride | Shire plc | NA | Chemical | Gastrointestinal Disorders | To treat chronic idiopathic constipation | 14-Dec-18 |
| Revcovi | Elapegademase-lvlr | Leadiant Biosciences | NA | Biological | Immunology / Genetic Disease | To treat Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID) | 5-Oct-18 |
| Oxervate | Cenegermin-bkbj | Dompà farmaceutici S.p.A | NA | Biological | Ophthalmology | To treat neurotrophic keratitis | 22-Aug-18 |
| Diacomit | Stiripentol | Biocodex SAS | NA | Chemical | Neurology / Neonatology | To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam | 20-Aug-18 |
| Omegaven | Fish Oil Triglycerides | Fresenius Kabi | NA | Chemical | Neonatology / Hepatology | As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis | 27-Jul-18 |
| Krintafel | Tafenoquine | Glaxosmithkline plc / Medicines for Malaria Venture | NA | Chemical | Infectious Diseases | For the radical cure (prevention of relapse) of Plasmodium vivax malaria | 20-Jul-18 |
| Tpoxx | Tecovirimat | Siga Technologies | NA | Chemical | Infectious Diseases | To treat smallpox | 13-Jul-18 |
| Moxidectin | Moxidectin | Medicines Development for Global Health | NA | Chemical | Infectious Diseases | To treat onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older | 13-Jun-18 |
| Lucemyra | Lofexidine Hydrochloride | US WorldMeds / Salix Pharmaceuticals | NA | Chemical | Pharmacology / Toxicology | For the non-opioid treatment for management of opioid withdrawal symptoms in adults | 16-May-18 |
| Akynzeo | Fosnetupitant And Palonosetron | Helsinn Healthcare | NA | Chemical | Oncology / Primary Care | To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy | 19-Apr-18 |
| Panzyga | Immune Globulin Intravenous (Human)-ifas | Octapharma Pharmazeutika Produktionsges.m.b.H. | NA | Biological | Hematology | Indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older and chronic immune thrombocytopenic purpura (ITP) in adults | 2-Aug-18 |
